The 2005 PT-141 sildenafil study found a stronger erection response with the combination than with sildenafil alone, measured in a laboratory. It involved 19 men who said Viagra or Levitra already worked for them. It did not establish better intercourse outcomes or show that the combination helped men for whom those medicines had failed.

That is the useful finding in Diamond and colleagues' Urology paper from 2005. PT-141 is also called bremelanotide. The experiment gives a reason to study the pairing further, with clear limits on what its result means outside the testing room.

What the PT-141 sildenafil study asked

The question was whether adding a low experimental amount of PT-141 changed the erection response to a low amount of sildenafil. Researchers also watched for added side effects.

This was a study of erectile dysfunction, meaning difficulty getting or keeping an erection. It was not a trial of low desire. The distinction matters because a recorded erection cannot tell researchers how interested someone feels or how satisfying sex is.

Who took part, and what did they receive?

The 19 participants reported responding to Viagra, which contains sildenafil, or Levitra, which contains vardenafil. Both belong to the PDE5-inhibitor family, medicines that support penile blood flow during sexual stimulation. Their previous response was based on what the men reported.

The design was a randomized crossover: treatment order was assigned by chance, and each man received the three conditions. Placebo means an inactive comparison treatment.

Study condition What researchers gave
Combination Sildenafil 25 mg plus PT-141 7.5 mg through the nose
Sildenafil comparison Sildenafil 25 mg plus inactive nasal spray
Inactive comparison Inactive tablet plus inactive nasal spray

These were 19 men in total, rather than 19 separate participants in each row. Comparing the same people across conditions helps account for differences between individuals. It does not make the sample representative of everyone with erection problems.

The amounts describe this experiment. They do not establish a dose for another preparation or person. The wider evidence for PT-141 in men comes from several studies with different populations and designs.

What RigiScan actually measured

RigiScan is a device that records erection firmness and duration. Researchers monitored participants for six hours after treatment. Within that period, the men had two 30-minute sessions of visual sexual stimulation.

The measured response therefore happened under arranged laboratory conditions. This was not six hours of intercourse, six hours of continuous sexual stimulation, or proof that an erection lasted the whole observation period.

A physical measurement can show that a drug combination changed the body's response. It cannot establish successful intercourse at home, a partner's experience, or lasting improvement after treatment ends.

The result: more response than sildenafil alone

The investigators reported a statistically significant increase in erection response with the combination compared with sildenafil plus inactive spray. Statistically significant means the difference met the study's test for being unlikely to arise from chance alone. It does not tell us that everyone benefited or that the difference would feel worthwhile to every patient.

There was no PT-141-only condition among the three comparisons. The design therefore cannot establish that the combination was better than PT-141 alone. Nor does its result settle whether adding PT-141 is preferable to changing sildenafil treatment under a clinician's care.

What the safety findings can support

The paper's published abstract summarizes safety this way:

Safety question Investigators' report
Did the combination introduce new side effects? No new side effects were reported compared with single-drug treatment.
Were side effects more frequent or severe? No increase in frequency or severity was reported compared with single-drug treatment.

That is a short-term observation in a small group. It is not a reliable estimate of uncommon harm, repeated-use risk, or safety in someone with heart disease. A study can find no added problem among its participants while leaving important risks unresolved.

Later studies must stay separate

A 2008 study by Safarinejad and Hosseini in The Journal of Urology enrolled men who had not responded to sildenafil. It compared nasal bremelanotide with placebo. That is a different question from adding PT-141 to sildenafil in men who already reported responding.

The journal issued an expression of concern in 2023, a formal notice raising concerns about that later paper. The notice concerns the 2008 study, rather than Diamond's 2005 combination experiment. Their populations, findings, and publication records should not be merged.

The later RECONNECT trials also asked a different question, in women with distressing low desire. The PT-141 clinical-trials guide explains that evidence; those results do not supply missing male combination outcomes.

The current label adds safety context

As of November 12, 2026, the day this article was written, the FDA's Vyleesi prescribing information reads “Revised: 10/2026.” It now includes measurements of bremelanotide transfer into human breast milk; effects on breastfed infants were not evaluated. Its labeled uses still do not include men or sexual-performance enhancement. The revision does not establish a PT-141–sildenafil treatment for men.

Vyleesi is contraindicated in uncontrolled high blood pressure or known heart or blood-vessel disease. Contraindicated means the medicine must not be used in those circumstances. The label describes temporary blood-pressure increases and a slower heart rate after each dose. A reassuring small experiment does not cancel those restrictions.

What this means for compounded PT-141

The 2005 experiment used a particular nasal preparation. Its result does not establish equivalent effects from a compounded medication, meaning one prepared by a pharmacy for an individual prescription. How a medicine is given, how it is prepared, and how much reaches the blood affect how directly a study applies.

PT-141 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product such as Vyleesi: the formulation offered here is not FDA-approved. FDA explains that it does not verify compounded drugs' safety, effectiveness, or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

What the individual review needs to settle

The useful details include the actual erection problem, previous response to treatment, blood-pressure readings, heart history, and the complete medication list. Sildenafil has its own risks and interactions; two medicines having different targets does not establish that combining them is suitable.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If treatment is prescribed, that clinician sets the actual dose and follow-up plan. The decision needs to fit the person seeking care, rather than simply reproduce a small laboratory experiment.